HEALTH OUTREACH PROGRAM FOR THE ELDERLY (HOPE)

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The BU Alzheimer's Disease Center (BU ADC) is one of 32 NIH funded centers mandated to provide research, education and clinical care related to Alzheimer's disease (AD). The BU ADC is comprised of 5 Cores: Administrative, Clinical, Education and Information Transfer, Neuropathology and Murine Breeding. The functions of research, education and clinical care are accomplished under the auspices of one of the five Cores. The Cores support several areas of emphasis or interest: genetic and environmental risks for AD, late stage dementia, family and professional care giving and studies involving African Americans. NIH has recently re-funded the BU ADC for a five years beginning July 2001. The primary purpose of the Clinical Core of the BU ADC is to promote research on AD at BU by providing information and materials from well characterized patient, control, and caregiver populations drawn from ambulatory and late-stage populations. The BU ADC has established a Registry called the Patient/Control Registry of the Clinical Core. It is comprised of participants with dementia and participants with normal cognition. Patients and controls enrolled in the Registry are assessed annually with a standardized neurological examination and neurophsychological test battery. Blood is obtained and stored for molecular genetic studies. A detailed medical, social, and family history is also obtained. This information is entered into a database for longitudinal comparisons and correlation with the progression of AD and its impact on caregivers. Subjects, data, and blood/DNA are made available to researchers to stimulate new research in AD and normal aging. .